Oncology resident at @CROAviano - @Uniud, ex-football referee ⚽️, runner 🏃♂️, big fan of @ACMilan
Joined December 2023
- Tweets8
- Following129
- Followers38
- Likes15
Can #fragmentomics become a new monitoring #biomarker in metastatic breast cancer? 🔬
👉 Here we explore a mutation-agnostic, cost-effective approach tested in the MAGNETIC.1 trial—a longitudinal study of first-line HR+/HER2- MBC.
doi.org/10.1016/j.tranon.202…
Lorenzo Foffano retweeted
🏁 Our program on cellular residual disease in triple negative breast cancer is about to launch!
Detecting circulating tumor cells in early #TNBC will provide deeper insights into the metastatic process and #immunotherapy response
#BreastCancer #LiquidBiopsy #CTC @CroAviano
Understanding mechanisms of resistance to CDK 4/6 inhibitors is crucial to refining the therapeutic algorithm for MBC. Could #liquidbiopsy be the game-changer we need? Find out more in our review, just published in The Breast👇
CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
sciencedirect.com/science/ar…
#bcsm #BreastCancer
Thrilled to present our poster at #SABCS24 on the use of #ctDNA in monitoring #MetastaticBreastCancer. #LiquidBiopsy RECIST are moving closer to clinical implementation—exciting times for precision oncology!
Intriguing data presented by @lfoffano97 at the #SABCS24 poster session on how #ctDNA can be leveraged to enhance disease monitoring in metastatic #BreastCancer.
Paving the way to a new #liquidbiopsy informed RECIST
@CtcLaboratory #PrecisionMedicine #bcsm
Lorenzo Foffano retweeted
Today we launched the "ISLB Global Survey: Oncologist Attitudes and Practices on Liquid Biopsy" to collect worldwide data on the use of liquid biopsy in clinical practice!
Help us sharing the survey with all the oncologists you know :)
docs.google.com/forms/d/e/1F…
Lorenzo Foffano retweeted
Circulating #tumor cells are a promising proxy #biomarker for endocrine #resistance, an emerging propriety deriving from mulitomic alterations.
👉 Here we explore this concept through a combined 🖥️ in-silico and 🧬 in-vivo approach. #liquidbiopsy #bcsm
sciencedirect.com/science/ar…
#ctDNA is gaining importance in #breastcancer. But what are its real clinical prospects? Excited to share our perspective: 'Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?' 👉 doi.org/10.1080/14737140.202…
Lorenzo Foffano retweeted
Check our companion posters on genetic and epigenetic #ctDNA profiling according to PR status in metastatic #breastcancer.
🔴during 1st line ET
🔼 ESR1 promoter methylation in PRpos
🔴after 1st line:
🔼ESR1 mut in PRpos #MBC
🔼GATA3 mut in PRneg #MBC
#SABCS23 #liquidbiopsy – at San Antonio, TX
